Clinical bottom line
Transforming growth factor-beta (TGF-β) is a central mediator of renal fibrosis, a key driver of chronic kidney disease (CKD) progression. Emerging anti-TGF-β therapies targeting this pathway offer a promising, yet still investigational, approach to reduce fibrosis and potentially slow CKD progression. Current evidence, largely preclinical and early-phase clinical, suggests modulation of TGF-β/Smad signaling may attenuate fibrotic remodeling in CKD. However, clinical efficacy and safety data remain limited, and these therapies are not yet ready for routine clinical use. Nephrologists should remain informed about ongoing developments as anti-TGF-β agents represent a putative disease-modifying strategy warranting further validation.
What the evidence shows
TGF-β plays a pivotal role in the pathogenesis of renal fibrosis by promoting extracellular matrix accumulation and fibroblast activation, contributing to irreversible kidney damage (Roy-Chaudhury et al., 2015). Targeting the TGF-β/Smad signaling axis has therefore emerged as a rational therapeutic strategy to mitigate fibrosis in CKD.
Recent reviews highlight multiple candidate agents, including monoclonal antibodies, receptor kinase inhibitors, and natural compounds, that inhibit TGF-β signaling and demonstrate anti-fibrotic effects in preclinical CKD models (International Journal of Frontiers in Medicine, 2025). These agents have shown the ability to reduce collagen deposition, suppress myofibroblast differentiation, and improve renal histology in animal studies, suggesting potential to alter disease trajectory.
Despite promising mechanistic data, clinical evidence remains sparse. Early-phase trials in related fibrotic diseases have reported variable efficacy and safety profiles, underscoring the complexity of TGF-β’s pleiotropic roles in tissue homeostasis and immunity (Roy-Chaudhury et al., 2015). Moreover, the heterogeneity of CKD etiologies and stages complicates patient selection and outcome assessment.
Traditional Chinese Medicine (TCM) therapeutics targeting TGF-β/Smad pathways have also been explored, with some compounds exhibiting anti-fibrotic properties in experimental CKD models (International Journal of Frontiers in Medicine, 2025). These findings provide additional avenues for investigation but require rigorous clinical validation.
Caveats and uncertainty
The TGF-β pathway is involved in multiple physiological processes beyond fibrosis, including immune regulation and cellular proliferation. Thus, systemic inhibition may carry risks of adverse effects such as impaired wound healing or immune dysregulation. The balance between therapeutic benefit and off-target toxicity remains a critical concern.
Most evidence to date derives from preclinical models or early-phase studies with small cohorts and short follow-up durations, limiting generalizability. There is a lack of large-scale randomized controlled trials demonstrating clear clinical benefit in CKD populations.
Additionally, CKD is a heterogeneous syndrome with diverse underlying causes and variable progression rates. The efficacy of anti-TGF-β therapies may differ across etiologies, and biomarkers to identify patients most likely to benefit are not yet established.
Finally, the long latency of CKD progression poses challenges for clinical trial design, requiring prolonged observation to detect meaningful changes in renal function or fibrosis.
How this may change practice
While anti-TGF-β therapies are not currently part of standard CKD management, ongoing research may soon clarify their role as adjunctive or disease-modifying treatments. Nephrologists should monitor emerging clinical trial data to identify candidates for future therapeutic incorporation.
In the near term, understanding the biology of TGF-β-mediated fibrosis can inform clinical reasoning and patient counseling regarding novel therapeutic avenues. Integration of fibrosis biomarkers and imaging may enhance patient stratification and treatment monitoring as these agents advance.
Collaborative efforts to design robust clinical trials and develop predictive biomarkers will be essential to translate anti-TGF-β strategies into practice. Until then, established CKD management focusing on blood pressure control, proteinuria reduction, and metabolic optimization remains paramount.